IXJ:NYE-iShares Global Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 86.93

Change

+0.19 (+0.22)%

Market Cap

N/A

Volume

0.07M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.57 (+0.41%)

USD 36.67B
FHLC Fidelity® MSCI Health Care In..

+0.15 (+0.23%)

USD 2.62B
FXH First Trust Health Care AlphaD..

+0.21 (+0.20%)

USD 1.09B
XHE SPDR® S&P Health Care Equipme..

+0.55 (+0.62%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.04 (+0.18%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.04 (-0.12%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+0.28 (+0.31%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.11 (+0.37%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.07 (+0.11%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.01 (+0.03%)

USD 0.01B

ETFs Containing IXJ

IXJ:AU iShares Global Healthcare.. 99.97 % 0.00 %

+2.08 (+1.52%)

USD 1.45B
XHC:CA iShares Global Healthcare.. 99.56 % 0.65 %

+0.11 (+1.52%)

CAD 0.54B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.24% 19% F 39% F
Dividend Return 1.49% 88% B+ 25% F
Total Return 1.73% 19% F 31% F
Trailing 12 Months  
Capital Gain 1.15% 24% F 43% F
Dividend Return 1.50% 88% B+ 25% F
Total Return 2.65% 38% F 35% F
Trailing 5 Years  
Capital Gain 26.10% 67% D+ 64% D
Dividend Return 7.93% 79% B- 23% F
Total Return 34.03% 71% C- 59% D-
Average Annual (5 Year Horizon)  
Capital Gain 5.88% 57% F 54% F
Dividend Return 6.83% 67% D+ 49% F
Total Return 0.96% 74% C 24% F
Risk Return Profile  
Volatility (Standard Deviation) 13.19% 81% B- 72% C
Risk Adjusted Return 51.80% 81% B- 67% D+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike